초록 ▼

Disclosed herein is a method for protecting humans in need of such protection from physical damage caused by ionizing radiation comprising administering to said humans on a defined basis prior to and after exposure to such radiation a plurality of antioxidants at a dosage level directly proportional

Disclosed herein is a method for protecting humans in need of such protection from physical damage caused by ionizing radiation comprising administering to said humans on a defined basis prior to and after exposure to such radiation a plurality of antioxidants at a dosage level directly proportional to the radiation level likely to be encountered.

대표청구항 ▼

What is claimed is: 1. A formulation consisting essentially of: Vitamin A (palmitate) 5,000 I.U. Beta-carotene (from natural D. salina) 15 mg Vitamin D-3 (cholecalciferol) 400 I.U. Natural soucre Vitamin E (d-alpha tocopherol) 100 I.U. (d-alpha tocopheryl acid succinat

What is claimed is: 1. A formulation consisting essentially of: Vitamin A (palmitate) 5,000 I.U. Beta-carotene (from natural D. salina) 15 mg Vitamin D-3 (cholecalciferol) 400 I.U. Natural soucre Vitamin E (d-alpha tocopherol) 100 I.U. (d-alpha tocopheryl acid succinate) 100 I.U. Buffered Vitamin C (calcium ascorbate) 500 mg Thiamine mononitrate 4 mg Riboflavin 5 mg Niacinamide ascorbate 30 mg d-calcium pantothenate 10 mg Pyridoxine hydrochloride 5 mg Cyanocobalamin 10 μg Folic Acid (Folacin) 800 μg D-Biotin 200 μg Selenium (1-seleno-methionine) 100 μg Chromium picolinate 50 μg Zinc glycinate 15 mg Calcium citrate 250 mg Magnesium citrate 125 mg and a booster formulation selected from a group consisting essentially of 1000 mg of vitamin C, 400 international units of d-alpha tocopheryl acid succinate, 200 international units of alpha tocopherol, 500 mg of N-acetyl cysteine, 50 mg of beta-carotene, and 100 mg of alpha lipoic acid, wherein said formulation is designed to reduce the risk in humans exposed to ionizing radiation of becoming subjected to at least one condition selected from the group consisting essentially of radiation-induced acute leukemia, breast cancer, and thyroid cancer. 2. The formulation of claim 1 wherein said dosage is taken prior to anticipated exposure. 3. The formulation of claim 1 wherein said dosage is taken after exposure. 4. The formulation of claim 1 wherein said formulation is taken by user after exposure for a period of at least seven days. 5. The formulation of claim 1 wherein said formulation is designed for a human who receives an effective dose of ionizing radiation of 0.5 mSv or less. 6. The formulation of claim 1 wherein said formulation is designed for a human who receives an effective dose of ionizing radiation of 0.5-5 mSv. 7. The formulation of claim 1 wherein said formulation is designed for a human who receives internal radionuclide exposures.